Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2017 (2017), Article ID 3175358, 9 pages
https://doi.org/10.1155/2017/3175358
Research Article

Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States

Department of Pharmacy Practice and Science, College of Pharmacy, The University of Arizona, Tucson, AZ, USA

Correspondence should be addressed to Sandipan Bhattacharjee

Received 3 January 2017; Accepted 13 April 2017; Published 27 April 2017

Academic Editor: Antonio Bertolotto

Copyright © 2017 Sandipan Bhattacharjee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Multiple Sclerosis Society (NMSS), Estimating the Prevalence of MS, http://www.nationalmssociety.org/About-the-Society/MS-Prevalence.
  2. R. A. Marrie, J. Cohen, O. Stuve et al., “A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview,” Multiple Sclerosis Journal, vol. 21, no. 3, pp. 263–281, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. R. C. Kessler, P. Berglund, O. Demler et al., “The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R),” Journal of the American Medical Association, vol. 289, no. 23, pp. 3095–3105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. Goldman Consensus Group, “The Goldman Consensus statement on depression in multiple sclerosis,” Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 11, no. 3, pp. 328–337, 2005. View at Google Scholar
  5. A. B. O'Connor, S. R. Schwid, D. N. Herrmann, J. D. Markman, and R. H. Dworkin, “Pain associated with multiple sclerosis: systematic review and proposed classification,” Pain, vol. 137, no. 1, pp. 96–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Schumann, M. Adamaszek, N. Sommer, and K. C. Kirkby, “Stress, depression and antidepressant treatment options in patients suffering from multiple sclerosis,” Current Pharmaceutical Design, vol. 18, no. 32, pp. 5837–5845, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Skokou, E. Soubasi, and P. Gourzis, “Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations,” ISRN Neurology, vol. 2012, Article ID 427102, 6 pages, 2012. View at Publisher · View at Google Scholar
  8. P. Brenner, K. Alexanderson, C. Bjorkenstam et al., “Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study,” PLoS ONE, vol. 9, no. 8, Article ID e104165, 2014. View at Publisher · View at Google Scholar
  9. S. M. Seyed Saadat, M. Hosseininezhad, B. Bakhshayesh, S. N. Seyed Saadat, and S. P. Nabizadeh, “Prevalence and predictors of depression in Iranian patients with multiple sclerosis: a population-based study,” Neurological Sciences, vol. 35, no. 5, pp. 735–740, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Sollom and II. Kneebone, “Treatment of depression in people who have multiple sclerosis,” Multiple Sclerosis, vol. 13, no. 5, pp. 632–635, 2007. View at Publisher · View at Google Scholar
  11. D. C. Mohr, S. L. Hart, I. Fonareva, and E. S. Tasch, “Treatment of depression for patients with multiple sclerosis in neurology clinics,” Multiple Sclerosis, vol. 12, no. 2, pp. 204–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Cetin, K. Johnson, D. Ehde, C. Kuehn, D. Amtmann, and G. Kraft, “Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample,” Multiple Sclerosis, vol. 13, no. 8, pp. 1046–1053, 2007. View at Publisher · View at Google Scholar
  13. “The Centers for Disease Control and Prevention (CDC): National Center for Health Statistics (NCHS),” Ambulatory Health Care Data http://www.cdc.gov/nchs/ahcd/index.htm.
  14. The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). Ambulatory Health Care Data: Questionnaires, Datasets, and Related Documentation: Estimation Procedures http://www.cdc.gov/nchs/ahcd/ahcd_estimation_procedures.htm.
  15. The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). Ambulatory Health Care Data: Data Collection and Processing http://www.cdc.gov/nchs/ahcd/ahcd_data_collection.htm.
  16. J. R. Avasarala, CA. O’Donovan, S. E. Roach, F. Camacho, and S. R. Feldman, “Analysis of NAMCS data for multiple sclerosis, 1998-–2004,” BMC Medicine, vol. 5, no. 6, 2007. View at Google Scholar
  17. I. S. Zenlea, C. E. Milliren, L. Mednick, and E. T. Rhodes, “Depression screening in adolescents in the united states: a national study of ambulatory office-based practice,” Academic Pediatrics, vol. 14, no. 2, pp. 186–191, 2014. View at Publisher · View at Google Scholar
  18. E. Hing, S. M. Schappert, C. W. Burt, and I. M. Shimizu, “Effects of form length and item format on response patterns and estimates of physician office and hospital outpatient department visits. National Center for Health Statistics,” Vital and Health Statistics. Series 2, Data Evaluation and Methods Research, vol. 2, no. 139, 2005. View at Google Scholar
  19. List of Antidepressant Medication Classes, https://online.statref.com/Document.aspx?
  20. J. G. Anderson and D. E. Bartkus, “Choice of medical care: a behavioral model of health and illness behavior,” Journal of Health and Social Behavior, vol. 14, no. 4, pp. 348–362, 1973. View at Google Scholar
  21. J. M. Bruce, L. M. Hancock, P. Arnett, and S. Lynch, “Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition,” Journal of Behavioral Medicine, vol. 33, no. 3, pp. 219–227, 2014. View at Google Scholar
  22. A. Lugaresi, M. R. Rottoli, and F. Patti, “Fostering adherence to injectable disease-modifying therapies in multiple sclerosis,” Expert Review of Neurotherapeutics, vol. 14, no. 9, pp. 1029–1042, 2014. View at Publisher · View at Google Scholar
  23. D. C. Mohr, A. C. Boudewyn, D. E. Goodkin, A. Bostrom, and L. Epstein, “Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis,” Journal of Consulting and Clinical Psychology, vol. 69, no. 6, pp. 942–949, 2001. View at Publisher · View at Google Scholar
  24. D. C. Mohr, W. Likosky, A. Bertagnolli et al., “Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis,” Journal of Consulting and Clinical Psychology, vol. 68, no. 2, pp. 356–361, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. M. T. Wallin, J. A. Wilken, A. P. Turner, R. M. Williams, and R. Kane, “Depression and multiple sclerosis: Review of a lethal combination,” The Journal of Rehabilitation Research and Development, vol. 43, no. 1, pp. 45–62, 2006. View at Publisher · View at Google Scholar
  26. J. P. Mostert, P. E. Sijens, M. Oudkerk, and J. De Keyser, “Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis,” Neuroscience Letters, vol. 402, no. 1-2, pp. 22–24, 2006. View at Publisher · View at Google Scholar
  27. J. Mostert, T. Heersema, M. Mahajan, J. Van Der Grond, M. A. Van Buchem, and J. De Keyser, “The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial,” ISRN Neurology, vol. 2013, Article ID 370943, 6 pages, 2013. View at Publisher · View at Google Scholar
  28. I. H. Li, W. S. Huang, C. Y. Shiue et al., “Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET,” NeuroImage, vol. 49, no. 2, pp. 1259–1270, 2010. View at Publisher · View at Google Scholar
  29. C. Solaro, R. Bergamaschi, C. Rezzani et al., “Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study,” Clinical Neuropharmacology, vol. 36, no. 4, pp. 114–116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C. I. Mitsonis, I. M. Zervas, C. M. Potagas et al., “Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study,” European Neuropsychopharmacology, vol. 20, no. 2, pp. 123–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. T. F. Scott, P. Nussbaum, H. McConnell, and P. Brill, “Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale,” Neurological Research, vol. 17, no. 6, pp. 421–422, 1995. View at Google Scholar
  32. D. M. Ehde, G. H. Kraft, L. Chwastiak et al., “Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis,” General Hospital Psychiatry, vol. 30, no. 1, pp. 40–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. K. O. Conner, V. C. Copeland, N. K. Grote et al., “Mental health treatment seeking among older adults with depression: the impact of stigma and race,” The American Journal of Geriatric Psychiatry, vol. 18, no. 6, pp. 531–543, 2010. View at Publisher · View at Google Scholar
  34. K. Rost, P. Nutting, J. Smith, J. C. Coyne, L. Cooper-Patrick, and L. Rubenstein, “The role of competing demands in the treatment provided primary care patients with major depression,” Archives of Familiy Medicine, vol. 9, no. 2, pp. 150–154, 2000. View at Google Scholar
  35. K. Richardson, K. Bennett, and R. A. Kenny, “Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults,” Age and Ageing, vol. 44, no. 1, pp. 90–96, 2015. View at Publisher · View at Google Scholar
  36. E. Spina, V. Santoro, and C. D'Arrigo, “Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update,” Clinical Therapeutics, vol. 30, no. 7, pp. 1206–1227, 2008. View at Publisher · View at Google Scholar